文献速递糖尿病肥胖与代谢综合征

二甲双胍改变健康年轻男性肠道菌群:非盲单臂干预研究

Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study.
PubMed 文献 · Diabetologia · 2019-03-23

该研究为18周单臂交叉试验,纳入27名健康年轻丹麦男性,干预期服用二甲双胍缓释片(每日两次,每次最多1g)。结果显示干预期间11个菌属相对丰度显著变化,停药后恢复基线;基线时12个菌属相对丰度可预测自我报告的胃肠道不良反应。

要点

  • 二甲双胍可改变糖代谢正常年轻男性的肠道菌群组成
  • 干预期间11个菌属丰度显著变化,停药后恢复至基线水平
  • 基线时12个菌属丰度可预测二甲双胍相关胃肠道不良反应

核心结论

  • 二甲双胍摄入会改变糖代谢正常年轻男性的肠道菌群组成,其变化延伸并验证了既往在2型糖尿病患者中的报告。
  • 基线肠道菌群组成可能是二甲双胍治疗后胃肠道不良反应发生的决定因素,需更大规模前瞻性研究验证。

研究设计与样本

  • 非盲、单臂、18周交叉试验,包含干预前、干预和干预后各6周。
  • 纳入27名健康年轻丹麦男性,年龄18-35岁,BMI 18.5-27.5 kg/m2,HbA1c < 39 mmol/mol(5.7%),血浆肌酐正常。
  • 干预期间给予二甲双胍,每日两次,每次最多1g。
  • 分析纳入完成第1次访视的23名参与者数据。

主要发现

  • 干预期间11个细菌菌属的相对丰度显著变化,治疗停止后恢复至基线水平。
  • 观察到Intestinibacter spp.和Clostridium spp.丰度降低,Escherichia/Shigella spp.和Bilophila wadsworthia丰度增加。
  • 基线时12个细菌菌属的相对丰度可预测自我报告的胃肠道不良反应。

临床怎么用

  • 提示二甲双胍对肠道菌群的影响在非糖尿病人群中同样存在,临床解读糖尿病患者菌群改变时需考虑二甲双胍的混杂效应。
  • 基线菌群特征可能有助于识别二甲双胍胃肠道不良反应高风险个体,但尚需进一步验证。

局限性

  • 研究为非盲、单臂设计,样本量较小(分析23人),结果需在更大规模前瞻性研究中重复验证。
  • 研究对象为健康年轻男性,结论外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Individuals with type 2 diabetes have an altered bacterial composition of their gut microbiota compared with non-diabetic individuals. However, these alterations may be confounded by medication, notably the blood-glucose-lowering biguanide, metformin. We undertook a clinical trial in healthy and previously drug-free men with the primary aim of investigating metformin-induced compositional changes in the non-diabetic state. A secondary aim was to examine whether the pre-treatment gut microbiota was related to gastrointestinal adverse effects during metformin treatment. METHODS: Twenty-seven healthy young Danish men were included in an 18-week one-armed crossover trial consisting of a pre-intervention period, an intervention period and a post-intervention period, each period lasting 6 weeks. Inclusion criteria were men of age 18-35 years, BMI between 18.5 kg/m2 and 27.5 kg/m2, HbA1c < 39 mmol/mol (5.7%) and plasma creatinine within the normal range. No prescribed medication, including antibiotics, for 2 months prior to recruitment were allowed and no previous gastrointestinal surgery, discounting appendectomy or chronic illness requiring medical treatment. During the intervention the participants were given metformin up to 1 g twice daily. Participants were examined five times in the fasting state with blood sampling and recording of gastrointestinal symptoms. Examinations took place at Frederiksberg Hospital, Denmark before and after the pre-intervention period, halfway through and immediately after the end of intervention and after the wash-out period. Faecal samples were collected at nine evenly distributed time points, and bacterial DNA was extracted and subjected to 16S rRNA gene amplicon sequencing in order to evaluate gut microbiota composition. Subjective gastrointestinal symptoms were reported at each visit. RESULTS: Data from participants who completed visit 1 (n=23) are included in analyses. For the primary outcome the relative abundance of 11 bacterial genera significantly changed during the intervention but returned to baseline levels after treatment cessation. In line with previous reports, we observed a reduced abundance of Intestinibacter spp. and Clostridium spp., as well as an increased abundance of Escherichia/Shigella spp. and Bilophila wadsworthia. The relative abundance at baseline of 12 bacterial genera predicted self-reported gastrointestinal adverse effects. CONCLUSIONS/INTERPRETATION: Intake of metformin changes the gut microbiota composition in normoglycaemic young men. The microbiota changes induced by metformin extend and validate previous reports in individuals with type 2 diabetes. Secondary analyses suggest that pre-treatment gut microbiota composition may be a determinant for development of gastrointestinal adverse effects following metformin intake. These results require further investigation and replication in larger prospective studies. TRIAL REGISTRATION: Clinicaltrialsregister.eu 2015-000199-86 and ClinicalTrials.gov NCT02546050 FUNDING: This project was funded by Danish Diabetes Association and The Novo Nordisk Foundation.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bryrup T, Thomsen CW, Kern T, et al. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study. Diabetologia. 2019. PMID: 30904939. doi:10.1007/s00125-019-4848-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。